Everolimus for Subependymal Giant-Cell Astrocytomas in Tuberous Sclerosis

By J. Stockman. 2012

595 citations recorded by the source corpus.

Subfields: Neurology, Physiology, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/5628b5bb2afcc4834d526e411e65a23147e18cb2

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Neurology

1. Jill S. Barnholtz-Sloan
2. Daniel C. Alexander
3. Darcy A. Krueger
4. Q. Ostrom
5. Hope Northrup

In Physiology

1. Darcy A. Krueger
2. Hope Northrup

In Pulmonary and Respiratory Medicine

1. Darcy A. Krueger
2. Hope Northrup

Citations in the corpus

• Tuberous Sclerosis Complex Surveillance and Management: Recommendations of the 2012 International Tuberous Sclerosis Complex Consensus Conference (2013, background): “Twelve subcommittees, each led by a clinician with advanced expertise in TSC and the relevant medical subspecialty, were organized to focus on specific disease focus topics that have important clinical management implications in TSC: (1) dermatology and dentistry; (2) nephrology; (3) pulmonology; (4”
• Multi-compartment microscopic diffusion imaging (2016, background): “Our findings have clear translational significance as SMT may help oversee treatment success in promising clinical trials (Franz et al., 2006; Bissler et al., 2008; Krueger et al., 2010; Tillema et al., 2012) where patients receive mTOR inhibitors such as everolimus and sirolimus.”
• Multifaceted role of mTOR (mammalian target of rapamycin) signaling pathway in human health and disease (2023, background): “gov, NCT00411619) in these patients.(268) Everolimus has reported promising anticancer efficacy in patients with pancreatic neuroendocrine tumors during clinical trials (RADIANT-3, NCT00510068) and received FDA approval.”
• Recent progress in pancreatic cancer (2013, background): “For example, the tyrosine kinase inhibitor sunitinib and the mammalian target of rapamycin (mTOR) pathway inhibitor everolimus have both been reported to significantly improve progression-free survival in patients with advanced PanNETs.72,73 Acinar carcinoma and pancreatoblastoma are rare usually so”
• Epidemiologic and Molecular Prognostic Review of Glioblastoma (2014, background): “The success of m-TOR pathway inhibition for subependymal giant-cell astrocytomas and the possibility of identifying a subtype of GBM sensitive to up-front treatment with bevacizumab are examples, but we need much more (142, 143).”